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Abstract
Obesity is an independent risk factor for severe influenza infection. However, the underlying cellular and
molecular mechanisms are still incompletely understood. In this study, we have utilized a murine influenza
infection model in genetic-induced obese (db/db) mice to explore the mechanisms by which obesity increases
host susceptibility to influenza infection. We find that db/db mice have enhanced viral replication, exaggerated
inflammatory responses, and dysregulated lung repair process after influenza infection, and consequently in-
creased host mortality. Furthermore, we demonstrate that the transcription factor peroxisome proliferator-activated
receptor-gamma (PPAR-c), an important inflammation regulator, was downregulated in the lung macrophages of
db/db mice after influenza infection. Strikingly, the treatment of 15-deoxy-D12, 14-prostaglandin J2 (15d-PGJ2), a
PPAR-c agonist, largely rescued the survival of db/db mice after influenza infection. Interestingly, macrophage
PPAR-c-deficient mice exhibited enhanced mortality after influenza infection and 15d-PGJ2 fails to rescue host
mortality in macrophage PPAR-c-deficient mice, suggesting that PPAR-c expression in macrophages is critical
for the action of 15d-PGJ2. These data indicate that obesity attenuates lung antiviral immunity and hampers
host recovery through the modulation of macrophage PPAR-c expression. Furthermore, modalities targeting
macrophage PPAR-c expression and/or function may serve as promising therapeutics to treat severe influenza
infection in obese patients.
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Introduction
Although majority of patients experience mildsymptoms, influenza virus infection kills *500,000 peo-
ple globally and up to 50,000 people in the United States each
year (61). High-risk populations such as young infants, aged
individuals, pregnant women, and asthmatics are often more
susceptible to influenza virus infection. In the 2009 H1N1
influenza pandemic, obese individuals were found to have
higher incidence, increased hospitalization, more severe
symptoms, and higher mortality compared with the general
population (26,34,37,59,68). It is now recognized that obesity
is an important independent risk factor for severe influenza
infection. Several previous studies have explored the poten-
tial mechanisms by which obesity increases host suscepti-
bility to influenza virus infection (12,25,44,45). For example,
the proinflammatory milieu caused by aberrant accumulation
of fat leads to the development of exaggerated inflammatory
responses after influenza infection (58). Obese hosts also
exhibited decreased titer of influenza-specific antibody and
diminished function of antiviral CD8 T cells, resulting in
delayed viral clearance and inflammation resolution (12,27).
Furthermore, overweight reduces lung functional residual
capacity as adipose tissue accumulated around chest and
abdomen decreases lung compliance, resulting in exacerba-
tion of flu infection (50). In addition, obese hosts also exhibit
defective lung wound healing responses, thereby impairing
lung damage repair after influenza infection (42). Although
these studies have provided insights into the interplay be-
tween obesity and influenza infection, the underlying mo-
lecular mechanisms by which obese hosts are susceptible to
severe influenza infection are still incompletely understood.
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Given the increasing prevalence of obesity worldwide (62), it
is critical to understand the underneath mechanism for the
purpose of influenza prevention and therapy.
Emerging evidence has suggested that lung macrophages
play an important role in modulating antiviral responses and
pulmonary inflammation after influenza infection. Obesity is
associated with the recruitment of large numbers of inflam-
matory macrophages to the adipose tissue (38,60). Further-
more, obesity alters adipose tissue macrophage phenotypes,
which drives persistent chronic inflammation in adipose tis-
sues and facilitates insulin resistance (18). However, the ef-
fect of obesity on lung macrophage phenotype and function
is unknown. The main macrophage population in the respi-
ratory tract is alveolar macrophages (AMs) that play impor-
tant roles in lung homeostasis and pulmonary antimicrobial
defense (11,23,29,32). A number of factors, including per-
oxisome proliferator-activated receptor-gamma (PPAR-c),
were recently shown to be important in AM development
and function (5,31,33,35,49).
PPAR-c is a nuclear transcription factor, which forms
complex with RXR (retinoid X receptor) for binding to
PPAR-responsive regulatory elements in genome to promote
gene transcription (1). In macrophages, PPAR-c acts to re-
strict excessive production of inflammatory factors by an-
tagonizing NF-jB function (30,46). Furthermore, PPAR-c
has been shown to be vital for the alternative polarization
of macrophages (M2 MF) (6,16,17,43). The deficiency of
PPAR-c in AM caused severe defects in the maturation of
AM compartment, suggesting that PPAR-c is essential for
AM development (35,52). Absence of PPAR-c in lung
macrophages causes enhanced Th1-biased inflammation and
defective resolution of inflammation (15). Notably, pro-
phylactic or therapeutic treatment of mice with natural or
synthetic ligands that activate PPAR-c leads to decreased
pulmonary inflammation and host diseases during influenza
virus infection (2,7,10,13,41), although the cellular mecha-
nisms by which PPAR-c agonists promote host protection
against influenza infection have not been defined.
In this report, we show that genetic-induced obese db/db
mice had enhanced host mortality after influenza infection.
db/db mice exhibited enhanced viral replication, increased
pulmonary inflammation, and decreased tissue recovery.
Furthermore, we demonstrate that macrophage PPAR-c is
downregulated in db/db mice after influenza infection.
PPAR-c agonist 15d-PGJ2 treatment reversed host mortality
after influenza infection. Our data suggest that the down-
regulation of PPAR-c expression and/or function may un-
derlie the enhanced host susceptibility to influenza virus
infection in obese hosts.
Materials and Methods
Mouse and infection
WT C57/BL6,db/+ heterozygous [B6.BKS(D)-Leprdb/J,
JAX: 000697], Lyz2-cre, Ppargfl/fl mice were purchased
from the Jackson Laboratory and bred in house. db/db mice
were obtained by crossing db/+ mice. PpargDLyz2 mice were
generated by crossing Ppargfl/fl mice with Lyz2-cre mice.
All control mice are age- and gender-matched WT mice
from the same litter. All mice housed in a specific pathogen-
free environment. For influenza virus infection, influenza
A/PR8/34 strain (*200 pfu/mouse) was diluted in fetal
bovine serum-free Dulbecco’s modified Eagle’s medium
media (Corning) on ice and inoculated in anesthetized mice
through intranasal route as described before (55). All mouse
procedures were approved by the Institutional Animal Care
and Use Committee (IACUC) of the Indiana University (No.
10006) or the Mayo Clinic (No. A00002027).
Lung single cell preparation
Mice were euthanized through overdose ketamine fol-
lowed by cervical dislocation. Lungs were perfused through
the right ventricle of the heart with 10 mL phosphate-
buffered saline (PBS) to remove blood mononuclear cells
from the vasculature [modified from a previous report (21)].
Subsequently, lung tissue was minced into small pieces
and enzymatically digested with type II collagenase (37C
for 30 min; Worthington), followed by passing through a
steel screen. RBCs in the cell suspensions were lysed using
ammonium chloride. Cells were counted using a hemo-
cytometer after exclusion of dead cells using Trypan blue
dye and suspended at appropriate concentrations for each
experiment.
Bronchoalveolar lavage cytokine assay
Bronchoalveolar lavage (BAL) was obtained by flushing
the airway multiple times with a single use of 600lL sterile
PBS for cytokine analysis as previously described (67).
Supernatants collected from first BAL flush were subjected
for cytokine measurement by Multiplex (Millipore) ac-
cording to the user manual. The result was read with
Luminex instrument and analyzed with Milliplex software
(Millipore).
Quantitative Reverse Transcriptase PCR
mRNA from the homogenates of the lungs as indicated in
the text was isolated with Total RNA purification kit (Sigma)
and treated with DNase I (Invitrogen) as previously described
(19). Random primers (Invitrogen) and MMLV reverse tran-
scriptase (Invitrogen) were used to synthesize first-strand
cDNAs from equivalent amounts of RNA from each sample.
Quantitative Reverse Transcriptase PCR (qPCR) was per-
formed with Fast SYBR Green PCR Master Mix (Applied
Biosystems). qPCR was conducted in duplicates in Quant-
Studio3 (Applied Bioscience). Data were generated with the
comparative threshold cycle (Delta CT) method by normal-
izing to hypoxanthine phosphoribosyl transferase. Sequences
of primers used in the studies will be provided upon request.
Mouse wound healing RT2 profiler PCR array
Total RNA from lung tissue was extracted as described
earlier. Equal amount of total RNA was used for the syn-
thesis of first-strand cDNA with kit from Qiagen. First-
strand cDNA was mixed with 2xFast SYBR Green Master
Mix (Applied Bioscience) and water in a formula directed in
the manual. Twenty-five microliters of the mixture was
added into each well of the 96-well plate provided by the
manufacturer. The wells in the plate include different
primers in each well to detect 84 target genes, housekeeping
genes, and negative and positive control genes. qPCR was
conducted in QuantStudio3 (Applied Bioscience). Obtained
raw data were analyzed in software provided by Qiagen
162 HUANG ET AL.
(accessible online on the website of Qiagen). Following the
instruction step by step, upload Excel file, designating
control group, select housekeeping gene to normalize result,
and calculate the relative expression quantity.
Western blot analysis
Fluorescence Acivated Cells Sorting (FACS)-sorted AMs
were lysed in lysis buffer (62.5 mM Tris-HCL [pH 6.8], 2%
SDS (sodium dodecyl sulfate) and 10% glycerol) with a
protease inhibitor cocktail (Roche). The lysates were then
separated by SDS-PAGE (SDS–polyacrylamide gel electro-
phoresis) and transferred to Immuno-Blot Nitrocellulose
Membrane (Bio-Rad). The membranes were blocked with 5%
nonfat milk in 20 mM Tris (pH 7.5), 0.5 M NaCl, and 0.05%
Tween 20 (TBST) for 1 h at room temperature, followed by
incubation with primary Ab against PPAR-c (1:1,000; Cell
Signaling Technology) or b-actin (1:5,000; Santa Cruz Bio-
technology) overnight at 4C. After washing with TBST
buffer, membranes were incubated with goat anti-rabbit or
anti-mouse secondary Ab (Promega). Peroxidase activity was
detected with enhanced chemiluminescence.
Plaque assay
Influenza plaque assays were performed as described
before (22,66). In brief, MDCK cells were grown in six-well
plates and incubated with series dilution of bronchoalveolar
lavage fluid (BALF) for 1 h. The plates were then overlaid
with low melting temperature agarose (0.6%) in minimum
essential medium (MEM) with bovine serum albumin and
trypsin and cultured for 3 days in 37C incubator. Plates
were then fixed with formaldehyde and virus plaques were
visualized with the staining of neutral red.
FACS analysis
Fluorescence-conjugated FACS Abs were purchased from
Biolegend, BD Biosciences or eBioscience. We defined cell
populations based on following cell surface markers: AM
(CD11c+ Siglec F+ CD11blow), NP366 tetramer
+ cells (CD8+
H2db NP366-tet
+). Samples were collected on FACS Attune
or FACS Attune NXT flow cytometer (Life Technologies),
and analyzed using Flow Jo software (Tree Star).
15d-PGJ2 treatment
15d-PGJ2 was purchased from Sigma (Cat. No. D8440)
and dissolved in methyl acetate (1 mg/mL). The vehicle was
replaced with PBS before administration through evapora-
tion by nitrogen gas. Owing to the short half-life time of
15d-PGJ2 in PBS, the vehicle replacement was done sepa-
rately one by one. 15d-PGJ2 was given by intra peritoneal
(IP) injection at 250 ng/g body weight daily from 1 to 12
d.p.i. (days postinfection).
Statistical analysis
Data are mean – standard error of the mean of values from
individual mice (in vivo experiments). Unpaired two-tailed
Student’s t-test (two group comparison), multiple t-tests
(weight loss), or log-rank test (survival study) were used to
determine statistical significance by GraphPad Prism soft-
ware. We consider p< 0.05 as significant.
Results
Enhanced host mortality and impaired viral clearance in
obese mice after influenza infection.
To explore the underneath mechanism of susceptibility of
obese individuals to influenza infection, a murine influenza
infection model was employed, in which we infected the
genetic-induced obese db/db mice with influenza A/PR8/34.
db/db mice harbor point mutations in the leptin receptor,
which resulted in obesity syndromes in mice (Fig. 1A) (9).
Consistent with reported observations (40,42), db/db mice
exhibited milder body weight loss compared with that of
control mice after influenza infection (Fig. 1A). However,
db/db mice showed significantly enhanced host mortality
after infection (Fig. 1B). The increased host mortality in
db/db mice was correlated with the failure of viral clearance
in db/db mice, as we observed significant higher influenza
titers in the lungs of db/db mice at 10 d.p.i. (Fig. 1C). Since
antiviral T cell responses are important in clearing influenza
virus from the lungs (4,54), we examined CD4 and CD8 T
cell responses in WT and db/db mice at day 7 and 10 p.i.
Strikingly, we found that both the total numbers of CD4,
CD8 T cells and the influenza antigen-specific CD8 T cells
[as enumerated through the staining of H2db NP366–374 tet-
ramer (NP)] were diminished in db/db mice than those in
control lean mice (Fig. 1D, E). Taken together, obesity leads
to decreased host antiviral immune response, which resulted
in enhanced viral replication and increased host mortality.
Enhanced lung inflammation and impaired
wound healing in obese mice
In addition to virus-induced lung damage, exuberant in-
flammatory responses also contribute to lung damage and
disease development after influenza infection. To this end, we
examined whether obese mice had enhanced pulmonary in-
flammation after influenza infection. The profiles of cytokines
and chemokines in BALF of WT or db/db mice were deter-
mined at 7 or 10 days after influenza infection. We found that
db/db mice showed widespread increased inflammatory cyto-
kine levels in BALF (Fig. 2A, B), indicating enhanced pul-
monary inflammation in db/db mice after influenza infection.
To return normal homeostasis, damaged lung tissues need
to be repaired after viral control. A previous study has
suggested that obese hosts have diminished lung repair (42),
although the molecular mechanisms underlying the phe-
nomena were not determined. To this end, we used Qiagen
wound healing PCR array method to examine lung re-
pair gene expression in WT or db/db mice at day 10 p.i. We
found that multiple wound healing genes were down-
regulated in the lungs of db/db mice at 10 d.p.i. compared
with control lean mice (Fig. 2C). Those downregulated genes
include epithelial and endothelial growth factors such as
vascular endothelial growth factor (VEGF), fibroblast growth
factor (FGF), and lung remodeling factors such as collagens
and matrix metalloproteinases (Fig. 2C, D). Together, these
data suggest that db/db mice had dysregulated damage repair
function after influenza infection. The re-expression of lung
type II alveolar epithelial cell (AEC II) genes are commonly
used as an indicator of lung injury repair (14). We, therefore,
determined AEC II gene expression and found that lungs
from db/db mice showed diminished expression of multiple
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AEC II genes than those of WT mice (Fig. 2E), confirming
the impaired damage repair in db/db lung.
Diminished PPAR-g expressions in lung macrophages
of db/db mice before and after influenza infection
Multiple immune cells are involved in orchestrating host
initial inflammatory reaction after influenza virus infection.
Among these cells, lung macrophages exhibit unique roles in
regulating inflammation, immunity, and repair after influenza
infection (64). We have recently showed that conditional
knockout of PPAR-c in macrophages led to enhanced in-
flammation and diminished damage repair after influenza
infection (20). Therefore, we wanted to determine whether
obesity could affect the expression of PPAR-c in lung mac-
rophages after influenza infection. Sorted lung macrophages
(CD45+CD64+/MERTK+) from naı¨ve mice and influenza-
infected mice were lysed and the amount of PPAR-c protein
in macrophages was directly measured by western blot. We
found that the protein levels of PPAR-c in lung macrophages
of db/db mice were modestly lower than those of control lean
mice before infection (day 0) (Fig. 3). Furthermore, PPAR-c
levels in lung macrophages were markedly decreased in
db/db mice compared with those in control lean mice after
influenza infection (5 and 9 d.p.i.). Together, these data in-
dicate that obesity suppresses the expression of PPAR-c in
lung macrophages after influenza infection.
15d-PGJ2 promotes macrophage PPAR-g-dependent
host recovery
We have shown previously that macrophage-specific
PPAR-c deficiency caused enhanced host morbidity and
mortality after influenza infection (20). Interestingly, a PPAR-
FIG. 1. Enhanced host mortality and impaired viral clearance in db/db mice after influenza infection. Littermate WT
control or db/db mice were infected with influenza PR8. (A) Host initial weight (left panel) and morbidity (% initial weight)
(right panel) after infection were monitored daily. (B) Host mortality (% survival) was monitored. (C) Airway influenza
titers (pfu/mL) were determined at day 10 p.i. (D) Numbers of total CD4, CD8 T cells in the lungs at day 7 or 10 p.i.
(E) Numbers of influenza-specific CD8 T cells (H2Db NP366–374 tetramer
+, NP CD8) in the lungs at day 7 or 10 p.i. Data are
representative of two experiments. Survival data were analyzed by log-rank (Mantel–Cox) test and all other data were
analyzed by two-tailed Student’s t-test. *Represents significant differences ( p < 0.05). Color images are available online.
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c agonist, 15d-PGJ2, could enhance host recovery in WT lean
mice (7), although the underlying cellular mechanisms are
not clear currently. We hypothesize that macrophage PPAR-c
expression is required for 15d-PGJ2 effects. To this end,
we infected control or macrophage-specific PPAR-c-deficient
mice (Lyz2-cre Ppargfl/fl mice, PpargDLyz2) with influenza and
then treated the mice with 15d-PGJ2. In control Ppargfl/fl mice,
15d-PGJ2 treatment exerted protective effects and amelio-
rated host morbidity (Fig. 4A). However, 15d-PGJ2 treatment
failed to increase host recovery and did not rescue the en-
hanced host mortality in PpargDLyz2 mice (Fig. 4B), suggest-
ing that the protective effects of 15d-PGJ2 against influenza
infection require PPAR-c expression in macrophages.
PPAR-g agonist treatment decreases
host mortality of db/db mice
The aforementioned data suggest that attenuated ex-
pression and/or activity of PPAR-c may contribute to the
FIG. 2. Enhanced inflammation and impaired wound healing in db/db mice. Littermate WT control or db/db mice were
infected with influenza PR8. (A) BAL cytokines levels in control or db/db mice at day 7 p.i. were determined by multiplex
cytokine analysis. (B) BAL cytokines levels in control or db/db mice at day 10 p.i. were determined by multiplex cytokine
analysis. (C) Comparison of the expression of 84 wound healing genes in the lungs at day 10 p.i. by RT2 Profiler PCR array.
Dotted line, fold cutoff of gene expression (1.5-fold). Red dots, genes upregulated in the lungs of db/db mice. Green dots,
genes downregulated in the lungs of db/db mice. (D) Repair-associated genes in the PCR array (C) that were downregulated
in the lungs of db/db mice. (E) qRT-PCR analysis of type II AEC genes expression at 10 d.p.i. (pooled cDNA samples from
two to three mice per group). Data are representative of at least two experiments. Data were analyzed by two-tailed
Student’s t-test. All graphs in (A) (B) represent significant differences ( p < 0.05). AEC, alveolar epithelial cell; BAL,
bronchoalveolar lavage; d.p.i. days postinfection; qRT-PCR, quantitative Real time PCR. Color images are available online.
FIG. 3. Diminished PPAR-c expression in lung macro-
phages of db/db mice. Littermate WT control or db/db
mice were infected with influenza PR8. Lung macrophages
(CD45+/MerTk+/CD64+/Ly6G-) were sorted before in-
fection (day 0) or at indicated days after infection. PPAR-c
and actin levels in the sorted macrophages were deter-
mined by western blot analysis. Data are representative of
at least two experiments. PPAR-c, peroxisome proliferator-
activated receptor-gamma.
PPAR-c AGONIST PROMOTES SURVIVAL IN OBESE HOSTS 165
enhanced disease development after influenza infection in
obese mice. We next sought to determine whether the
stimulation of PPAR-c activity could ameliorate host dis-
eases after influenza infection in obese mice. To this end, we
infected WT or db/db mice with influenza and then treated the
mice with 15d-PGJ2. As reported (3,7), 15d-PGJ2 treatment
enhanced host recovery in lean mice as 15d-PGJ2-treated
mice exhibited earlier body weight regains (Fig. 5A). Strik-
ingly, 15d-PGJ2 treatment promoted db/db mouse survival,
rising from 11% to 55% survival rate (Fig. 5B). Together,
data in Figures 4 and 5 indicate that enforced macrophage
PPAR-c activation may attenuate host disease development
after influenza infection in obese hosts.
Discussion
Obesity is known to be an independent risk factor asso-
ciated with various disorders such as cardiovascular diseases
and type 2 diabetes. Recently, obesity was also identified as
a risk factor for severe influenza infection (8,39,65). Con-
sistent with the clinical findings, obese mice exhibit in-
creased mortality, enhanced lung inflammatory responses,
and impaired tissue recovery when compared with control
lean mice (53). Our results are consistent with those re-
ported findings. Furthermore, we have demonstrated that
obese mice have altered antiviral adaptive immune re-
sponses, impaired viral clearance, decreased wound healing
gene expression, and defective regeneration of lung AEC II
cells. These altered host responses to influenza infection
likely all contribute to the enhanced host mortality after
influenza infection in obese mice.
Macrophages are important regulators of host responses
against influenza infection (51). Absence of the major lung
resident macrophage population, that is, AM, results in
severe lung damage and enhanced host mortality after in-
fluenza infection (5,31,49,51). Conversely, diminished re-
cruitment of inflammatory monocytes and macrophages
leads to decreased host inflammation and disease develop-
ment (36). Thus, different macrophage populations may
exhibit distinct function to influenza infection. Currently,
the transcriptional regulation of lung macrophage function
during influenza virus infection is poorly understood. We
recently have identified that PPAR-c deficiency in macro-
phages led to enhanced pulmonary inflammation and di-
minished lung repair at acute phase (20). In this report, we
have found that obesity decreased the anti-inflammatory
transcription factor, PPAR-c, expression in lung macro-
phages before and after influenza infection. Consistent with
the observation, obese mice exhibited enhanced pulmonary
inflammation and impaired tissue repair, which mimic the
phenotypes observed in the macrophage-specific PPAR-c-
deficient mice. Together these data suggest that diminished
PPAR-c expression and/or activity in macrophages could
underlie the enhanced susceptibility to severe influenza in-
fection in obese hosts.
In support of this idea, 15d-PGJ2 treatment improved
the poor outcome of infected obese mice. Furthermore, the
specific deletion of PPAR-c in macrophages abolished the
effects of 15d-PGJ2 treatment. Thus, our data have provided
a viable mechanism by which obesity increases host sus-
ceptibility to influenza infection. Nevertheless, obesity is
likely to pose significant effects on multiple cell types and
FIG. 4. Deletion of PPAR-c in macrophages abolishes the effect of 15d-PGJ2. WT littermate control (Ppargfl/fl) or
PpargDLyz2 mice were infected with influenza PR8 and treated with vehicle or 15d-PGJ2. (A) Host morbidity (% initial
weight) after infection was monitored daily. (B) Host mortality (% survival) was monitored. Data are pooled from two
experiments. Survival data were analyzed by log-rank (Mantel–Cox) test and weight loss data were analyzed by multiple
t-test. *Represents significant differences ( p< 0.05). Color images are available online.
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molecular pathways to increase host susceptibility to severe
influenza infection. For instance, reduced antiviral type I
interferon production and/or signaling due to the increased
suppressor of cytokine signaling (SOCS) activities may also
contribute to the severe influenza infection in obese mice
(47). Of note, we have not examined the mechanisms of
action by which 15d-GPJ2 treatment inhibits host mortality
after influenza infection in obese mice. A previous report
has suggested that 15d-PGJ2 treatment can simultaneously
promote viral control and suppress host inflammation (7).
Thus, it is possible that 15d-PGJ2 could restore viral control
and inhibit inflammatory responses in db/db mice. Further-
more, 15d-PGJ2 may also promote lung repair process in
db/db mice since PPAR-c expression in macrophages is
important in tissue repair after influenza infection (20).
Future studies are needed to explore these possibilities.
Delayed or impaired wound healing responses are a dis-
tinguishing feature of obesity subjects (42). Obesity can lead
to impaired cutaneous repair commonly found in surgery
patients (48). We found that obese mice exhibited a general
trend of downregulation of wound repair genes at day 10
postinfection, when normal lean mice started to recover their
weight and repair the damaged lung tissues (42,56,57). These
data indicate that obesity also dysregulates the healing re-
sponses to lung wound in addition to the cutaneous wound.
Of note, macrophages are critical regulators of wound repair
responses. They can phagocytose cells debris, release healing
cytokines and chemokines, and recruit various other helper
cells to create optimistic environment for tissue remodeling
(63,64). We speculate that obesity may directly interfere with
macrophage-mediated wound healing responses through the
downregulation of PPAR-c. PPAR-c expression in macro-
phages is important for their expression of multiple epithelial
and endothelial growth factors (20,24,28). However, it is also
possible that increased viral replication and/or increased
pulmonary inflammation may contribute to the decreased
wound healing responses observed in obese mice. Future
studies are warranted to explore these possibilities.
In summary, we have identified that obesity dysregulates
host antiviral, inflammatory, and reparative responses, po-
tentially through the inhibition of macrophage function
through PPAR-c downregulation. Furthermore, our data
suggest that drugs that can stimulate macrophage PPAR-c
function may serve as promising therapeutics to treat severe
influenza infection in obese patients.
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